Interesting from Sto....ead this morning.
Galan Lithium has outlined compelling economics for Phase 1 of its Hombre Muerto West (HMW) project, which will see initial production of 5,370tpa of LCE equivalent, up from the expected 4,000tpa.
At a capital cost of US$104m (minus contingency) and operational expenses of US$3,963/t of recoverable LCE, Phase 1 will deliver a post-tax NPV 8% of US$460m, IRR of 36% and free cash flow of US$54m per year – and with a payback period of about two years, it will facilitate funding for further expansions.
The Phase 1 DFS is part of Galan Lithium’s (ASX:GLN) four-phase approach to building out its HMW and Candelas projects to a final output of 60,000ktpa.
The two projects have a combined resource of 7.3Mt at 852mg/l Li – with HMW providing the bulk of this at 6.6Mt LCE at 880m/l Li – giving the company one of the highest grade, large scale resources in the brine-rich Catamarca region.
- Forums
- ASX - By Stock
- LKE
- Level-headed, blunt assessment of Lake Resources
Level-headed, blunt assessment of Lake Resources, page-333
-
- There are more pages in this discussion • 167 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add LKE (ASX) to my watchlist
|
|||||
Last
3.8¢ |
Change
-0.002(5.00%) |
Mkt cap ! $63.40M |
Open | High | Low | Value | Volume |
4.0¢ | 4.1¢ | 3.8¢ | $230.1K | 5.879M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
45 | 4289511 | 3.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.9¢ | 160348 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 65000 | 0.039 |
38 | 2831698 | 0.038 |
27 | 2638725 | 0.037 |
26 | 1864530 | 0.036 |
31 | 3937186 | 0.035 |
Price($) | Vol. | No. |
---|---|---|
0.036 | 31036 | 1 |
0.038 | 34778 | 1 |
0.039 | 215923 | 4 |
0.040 | 638448 | 9 |
0.041 | 562845 | 5 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
LKE (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online